2 recruiting, 1 not yet recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
Follow Beihua Kong: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer Ovarian Cancer | Not yet recruiting | Beihua Kong | 32 | 2025-09-01 | 2025-09-04 | |
| TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors Paclitaxel, Carboplatin, Bleomycin - Ovarian Germ Cell Cancer, Ovarian Neoplasms | Phase 3 | Recruiting | Beihua Kong | 129 | 2015-04-01 | 2023-04-25 |
| TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors Paclitaxel, Carboplatin, Bleomycin - Ovarian Sex Cord Stromal Tumor, Ovarian Neoplasms | Phase 3 | Recruiting | Beihua Kong | 132 | 2015-04-01 | 2023-04-25 |
Ovarian Neoplasms (3) · Ovarian Germ Cell Cancer (1)
Bleomycin (2) · Carboplatin (2) · Cisplatin (2) · Etoposide (2) · Paclitaxel (2) · Taxes (2) · etoposide phosphate (2)
China (2)